Literature DB >> 18780827

Comparison of dynamic susceptibility-weighted contrast-enhanced MR methods: recommendations for measuring relative cerebral blood volume in brain tumors.

Eric S Paulson1, Kathleen M Schmainda.   

Abstract

PURPOSE: To investigate whether estimates of relative cerebral blood volume (rCBV) in brain tumors, obtained by using dynamic susceptibility-weighted contrast material-enhanced magnetic resonance (MR) imaging vary with choice of data acquisition and postprocessing methods.
MATERIALS AND METHODS: Four acquisition methods were used to collect data in 22 high-grade glioma patients, with informed written consent under HIPAA-compliant guidelines approved by the institutional review board. During bolus administration of a standard single dose of gadolinium-based contrast agent (0.1 mmol per kilogram of body weight), one of three acquisition methods was used: gradient-echo (GRE) echo-planar imaging (echo time [TE], 30 msec; flip angle, 90 degrees ; n = 10), small-flip-angle GRE echo-planar imaging (TE, 54 msec; flip angle, 35 degrees ; n = 7), or dual-echo GRE spiral-out imaging (TE, 3.3 and 30 msec; flip angle, 72 degrees ; n = 5). Next, GRE echo-planar imaging (TE, 30 msec; flip angle, 90 degrees ; n = 22) was used to collect data during administration of a second dose of contrast agent (0.2 mmol/kg). Subsequently, six methods of analysis were used to calculate rCBV. Mean rCBV values from whole tumor, tumor hot spots, and contralateral brain were normalized to mean rCBV in normal-appearing white matter.
RESULTS: Friedman two-way analysis of variance and Kruskal-Wallis one-way analysis of variance results indicated that qualitative rCBV values were dependent on acquisition and postprocessing methods for both tumor and contralateral brain. By using the nonparametric Mann-Whitney test, a consistently positive (greater than zero) tumor-contralateral brain rCBV ratio resulted when either the preload-postprocessing correction approach or dual-echo acquisition approach (P < .008 for both methods) was used.
CONCLUSION: The dependence of tumor rCBV on the choice of acquisition and postprocessing methods is caused by their varying sensitivities to T1 and T2 and/or T2* leakage effects. The preload-correction approach and dual-echo acquisition approach are the most robust choices for the evaluation of brain tumors when the possibility of contrast agent extravasation exists. (c) RSNA, 2008.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18780827      PMCID: PMC2657863          DOI: 10.1148/radiol.2492071659

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  46 in total

Review 1.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

2.  Evaluation of four postprocessing methods for determination of cerebral blood volume and mean transit time by dynamic susceptibility contrast imaging.

Authors:  Jussi Perkiö; Hannu J Aronen; Aki Kangasmäki; Yawu Liu; Jari Karonen; Sauli Savolainen; Leif Østergaard
Journal:  Magn Reson Med       Date:  2002-05       Impact factor: 4.668

Review 3.  Histologic measures of angiogenesis in human primary brain tumors.

Authors:  Rebecca D Folkerth
Journal:  Cancer Treat Res       Date:  2004

4.  Perfusion imaging with NMR contrast agents.

Authors:  B R Rosen; J W Belliveau; J M Vevea; T J Brady
Journal:  Magn Reson Med       Date:  1990-05       Impact factor: 4.668

5.  Characterization of a first-pass gradient-echo spin-echo method to predict brain tumor grade and angiogenesis.

Authors:  Kathleen M Schmainda; Scott D Rand; Allen M Joseph; Rebecca Lund; B Doug Ward; Arvind P Pathak; John L Ulmer; Michael A Badruddoja; Michael A Baddrudoja; Hendrikus G J Krouwer
Journal:  AJNR Am J Neuroradiol       Date:  2004-10       Impact factor: 3.825

6.  Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade.

Authors:  Meng Law; Stanley Yang; James S Babb; Edmond A Knopp; John G Golfinos; David Zagzag; Glyn Johnson
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

Review 7.  Expanding the clinical development of bevacizumab.

Authors:  Helen X Chen
Journal:  Oncologist       Date:  2004

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Perfusion MR imaging: clinical utility for the differential diagnosis of various brain tumors.

Authors:  Sung Ki Cho; Dong Gyu Na; Jae Wook Ryoo; Hong Gee Roh; Chan Hong Moon; Hong Sik Byun; Jong Hyun Kim
Journal:  Korean J Radiol       Date:  2002 Jul-Sep       Impact factor: 3.500

10.  Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI.

Authors:  Glyn Johnson; Stephan G Wetzel; Soonmee Cha; James Babb; Paul S Tofts
Journal:  Magn Reson Med       Date:  2004-05       Impact factor: 4.668

View more
  140 in total

1.  Percentage signal recovery derived from MR dynamic susceptibility contrast imaging is useful to differentiate common enhancing malignant lesions of the brain.

Authors:  R Mangla; B Kolar; T Zhu; J Zhong; J Almast; S Ekholm
Journal:  AJNR Am J Neuroradiol       Date:  2011-04-21       Impact factor: 3.825

Review 2.  Multimodality Brain Tumor Imaging: MR Imaging, PET, and PET/MR Imaging.

Authors:  James R Fink; Mark Muzi; Melinda Peck; Kenneth A Krohn
Journal:  J Nucl Med       Date:  2015-08-20       Impact factor: 10.057

3.  Cerebral blood volume mapping with ferumoxytol in dynamic susceptibility contrast perfusion MRI: Comparison to standard of care.

Authors:  Csanad G Varallyay; Eric Nesbit; Andrea Horvath; Peter Varallyay; Rongwei Fu; Seymur Gahramanov; Leslie L Muldoon; Xin Li; William D Rooney; Edward A Neuwelt
Journal:  J Magn Reson Imaging       Date:  2018-01-04       Impact factor: 4.813

4.  Quantitative cerebral blood flow in dynamic susceptibility contrast MRI using total cerebral flow from phase contrast magnetic resonance angiography.

Authors:  David Bonekamp; Mahaveer Degaonkar; Peter B Barker
Journal:  Magn Reson Med       Date:  2011-02-01       Impact factor: 4.668

5.  Perfusion magnetic resonance imaging in pediatric brain tumors.

Authors:  F Dallery; R Bouzerar; D Michel; C Attencourt; V Promelle; J Peltier; J M Constans; O Balédent; C Gondry-Jouet
Journal:  Neuroradiology       Date:  2017-08-31       Impact factor: 2.804

6.  Effects of perfusion on diffusion changes in human brain tumors.

Authors:  Alexander D Cohen; Peter S LaViolette; Melissa Prah; Jennifer Connelly; Mark G Malkin; Scott D Rand; Wade M Mueller; Kathleen M Schmainda
Journal:  J Magn Reson Imaging       Date:  2013-02-06       Impact factor: 4.813

7.  Differentiation of hemangioblastomas from pilocytic astrocytomas using 3-T magnetic resonance perfusion-weighted imaging and MR spectroscopy.

Authors:  D J She; Z Xing; Z Zeng; X Y Shang; D R Cao
Journal:  Neuroradiology       Date:  2014-12-07       Impact factor: 2.804

8.  Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

Authors:  Melissa A Prah; Mona M Al-Gizawiy; Wade M Mueller; Elizabeth J Cochran; Raymond G Hoffmann; Jennifer M Connelly; Kathleen M Schmainda
Journal:  J Neurooncol       Date:  2017-09-12       Impact factor: 4.130

9.  MRI Evaluation of Non-Necrotic T2-Hyperintense Foci in Pediatric Diffuse Intrinsic Pontine Glioma.

Authors:  O Clerk-Lamalice; W E Reddick; X Li; Y Li; A Edwards; J O Glass; Z Patay
Journal:  AJNR Am J Neuroradiol       Date:  2016-05-19       Impact factor: 3.825

10.  Impact of perfusion map analysis on early survival prediction accuracy in glioma patients.

Authors:  Benjamin Lemasson; Thomas L Chenevert; Theodore S Lawrence; Christina Tsien; Pia C Sundgren; Charles R Meyer; Larry Junck; Jennifer Boes; Stefanie Galbán; Timothy D Johnson; Alnawaz Rehemtulla; Brian D Ross; Craig J Galbán
Journal:  Transl Oncol       Date:  2013-12-01       Impact factor: 4.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.